EUVIMEDEUVIMED entdecken
Crossref

Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics

Zhengwen Cai iD, Long Bai, Qiumei Li, Yong Li, Xiaoxiao Cai iD, Yunfeng Lin iD

ACS Nano · 31.12.2024 · 18 (52) · 35214-35229

DOI: 10.1021/acsnano.4c08727 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 17.12.2024. Verfasst von Zhengwen Cai und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of S…. Hauptthemen laut MEDLINE: Sirtuin 1, Osteoporosis, Nucleic Acids. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, Sichuan Province Youth Science and Technology Innovation Team, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic osteoporosis, a prevalent chronic complication of diabetes, is marked by reduced bone mass, increased bone fragility, and susceptibility to fractures. A significant cause of this condition is the disruption of osteoblastic homeostasis due to prolonged hyperglycemia, which impedes bone regeneration and remodeling. Despite its prevalence, no effective treatments specifically target diabetic osteoporosis. Recently, small-activating RNA (saRNA) therapy has attracted attention for its targeting capacity, high efficacy, and minimal side effects. However, RNA's inherent properties, such as structural instability, susceptibility to degradation, and poor penetration, limit its applications. To address these limitations, a gene-activating tetrahedral framework nucleic acid (tFNA) with sirtuin-1 (SIRT1) gene activation function is developed, termed Tsa. Tsa exhibits an RNA-protecting effect and can effectively penetrate cell membranes to upregulate SIRT1 gene expression. At the histological level, Tsa treatment alleviates diabetic osteoporosis by increasing bone trabecular density and promoting new bone formation. At the cellular level, it switches macrophage polarization toward the anti-inflammatory M2 phenotype while inhibiting the inflammatory M1 phenotype, creating a favorable bone immune microenvironment for osteoblasts. At the genetic level, Tsa activates SIRT1 expression, which deacetylates Acetyl-p65 to block the NF-κB pathway and restore the osteoimmune environment. Overall, this research demonstrates a nanodrug "Tsa", capable of activating SIRT1 and modulating the bone immune environment, thereby showcasing its immense potential for diabetic osteoporosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 1OsteoporosisNucleic AcidsAnimalsMiceUp-RegulationHumansRAW 264.7 CellsMice, Inbred C57BLMaleOsteoblastsOsteogenesisDiabetes Mellitus, Experimental

Stichwörter der Autor:innen

diabetic osteoporosismacrophageosteoblastosteoimmunologysirtuin-1small-activating RNAtetrahedral framework nucleic acid

Substanzen

Sirtuin 1Nucleic Acids

Autor:innen und Institutionen

  • State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China.
  • Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu 610041, Sichuan, China.
  • Department of Oral Implantology, The Affiliated Stomatological Hospital of Southwest Medical University, Luzhou 646000, China.
  • National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200240, China.

ORCID-Profile: Zhengwen Cai, Xiaoxiao Cai, Yunfeng Lin

Förderung

  • West China Hospital, Sichuan University
  • Sichuan Province Youth Science and Technology Innovation Team
  • National Natural Science Foundation of China
  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Cai, Z., Bai, L., Li, Q., Li, Y., Cai, X., & Lin, Y. (2024). Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics. ACS Nano, 18(52), 35214-35229. https://doi.org/10.1021/acsnano.4c08727

Vancouver

Cai Z, Bai L, Li Q, Li Y, Cai X, Lin Y. Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics. ACS Nano. 2024;18(52):35214-35229. doi:10.1021/acsnano.4c08727

BibTeX
@article{Cai2024,
  author = {Cai, Zhengwen and Bai, Long and Li, Qiumei and Li, Yong and Cai, Xiaoxiao and Lin, Yunfeng},
  title = {Gene-Activating Framework Nucleic Acid-Targeted Upregulating Sirtuin-1 to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis Therapeutics},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {52},
  pages = {35214--35229},
  doi = {10.1021/acsnano.4c08727}
}
Kostenlos starten →